The focus of the 179th Meeting of Vaccines and Related Biological Products Advisory Committee was on the biologics license application for respiratory syncytial virus (RSV) vaccine recombinant, Adjuvanted (AREXVY). Experts provided an overview of RSV, description of AREXVY, clinical trials submitted in support of AREXVY licensure, and voting questions for the committee.